Liraglutide 10mg
A long-acting GLP-1 receptor agonist investigated in metabolic research models for appetite regulation, glycemic control, and weight loss.
Mechanism
Liraglutide selectively stimulates the GLP-1 receptor, amplifying glucose-mediated insulin secretion, delaying gastric transit, and modulating hypothalamic feeding pathways.
Dosing
Standard laboratory protocols initiate administration at 0.6 mg daily and escalate stepwise at weekly intervals.
Reconstitution
Adding 2.0 mL of bacteriostatic water to a 10 mg lyophilized vial produces a working concentration of 5 mg/mL.
Storage
Store unmixed vials refrigerated or frozen protected from light; once reconstituted, refrigerate at 2–8 °C and utilize within roughly 28 days.
Mix & measure Liraglutide 10mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Liraglutide 10mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 16.7
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Week 1 | 0.6 mg (1× daily) | 12 units (0.12 mL) |
| Week 2 | 1.2 mg (1× daily) | 24 units (0.24 mL) |
| Week 3 | 1.8 mg (1× daily) | 36 units (0.36 mL) |
| Week 4 | 2.4 mg (1× daily) | 48 units (0.48 mL) |
| Week 5+ | 3.0 mg (1× daily) | 60 units (0.60 mL) |
Reconstitution Steps
- 1
Clean the rubber stoppers of both the liraglutide vial and bacteriostatic water vial using sterile alcohol wipes.
- 2
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
- 3
Insert the needle at a slight angle and direct the stream gently down the glass wall rather than directly onto the lyophilized cake.
- 4
Gently rotate or swirl the vial until the peptide completely dissolves without shaking.
- 5
Mark the preparation date on the vial and transfer it to refrigerated storage at 2–8 °C.
Supplies Needed
Peptide Vial
Contains 10 mg of lyophilized liraglutide for research handling
Insulin Syringes (U-100)
Facilitates precise measurement and micro-volume subcutaneous experimental delivery
Bacteriostatic Water
Provides 2.0 mL of sterile, preserved diluent to reconstitute the lyophilized powder
Alcohol Swabs
Used to disinfect vial stoppers and work surfaces to maintain sterile technique
Why researchers study it
Investigation of body-weight modulation and adiposity reduction
Analysis of glycemic control and HbA1c reduction pathways
Appetite suppression and central satiety signaling models
Cardiovascular risk profile and endothelial outcomes in metabolic models
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Liraglutide is a synthetic analogue of mammalian glucagon-like peptide-1 (GLP-1), engineered to resist rapid enzymatic degradation via dipeptidyl peptidase-4 (DPP-4). By incorporating a sixteen-carbon fatty-acid side chain, the peptide self-associates and binds reversible circulating albumin, substantially prolonging its operational half-life to roughly 13 hours and enabling reliable once-daily experimental regimens. In preclinical and clinical research contexts, liraglutide serves as a benchmark incretin mimetic for metabolic investigations. It is extensively evaluated for its dual impact on endocrine pancreatic function and central nervous system appetite centers, facilitating standardized study designs exploring nutrient absorption kinetics, caloric intake reduction, and long-term metabolic health.
References
- 1.Knudsen & Lau, Drug Design, Development and Therapy, 2019 — Discovery and mechanism of GLP-1 receptor agonists
- 2.FDA Prescribing Information, Victoza, 2017 — Type 2 diabetes indication and clinical safety
- 3.FDA Prescribing Information, Saxenda, 2020 — Chronic weight management dosing and safety profile
- 4.Journal of Medicinal Chemistry, 2000 — Fatty-acid acylation and pharmacological longevity of liraglutide
- 5.Pi-Sunyer et al., New England Journal of Medicine, 2015 — Randomized clinical trial of liraglutide 3.0 mg for weight management
- 6.Marso et al., New England Journal of Medicine, 2016 — Cardiovascular outcomes with liraglutide in high-risk diabetes cohorts
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allPemvidutide 5mg
Investigational GLP-1/glucagon dual agonist evaluated in clinical models for targeted hepatic fat clearance and metabolic regulation.
View ProtocolAcetyl Tetrapeptide-3 1-5% (blend)
Topical biomimetic tetrapeptide studied for follicular anchoring and extracellular matrix support in cosmetic hair research.
View ProtocolHGH Fragment 176-191 5mg
A truncated C-terminal human growth hormone peptide investigated in laboratory settings for lipolytic signaling without glycemic perturbation.
View Protocol